IFP Advisors’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

IFP Advisors’s Portfolio NVIV Stock Details NVIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1	Closed	-$1K	–	4682
2022 Q4	$1K	Sell	1 -1	-50%	-$3	﹤0.01%	4577
2022 Q3	$2K	Hold	2	–	–	﹤0.01%	4481
2022 Q2	$2K	Buy	+2	New	+$11	﹤0.01%	4259
2022 Q1	–	Hold	0	–	–	–	4257
2019 Q1	–	Hold	0	–	–	–	3919
2018 Q4	–	Hold	0	–	–	–	4108
2018 Q3	–	Hold	0	–	–	–	4171
2018 Q2	–	Hold	0	–	–	–	4227
2018 Q1	–	Hold	0	–	–	–	3914
2017 Q4	–	Sell	-1	Closed	-$23.1K	–	4332
2017 Q3	$15K	Buy	+1	New	+$30.7K	﹤0.01%	2810
2017 Q2	–	Hold	0	–	–	–	2460
2017 Q1	–	Hold	0	–	–	–	2188
2016 Q4	–	Hold	0	–	–	–	2113
2016 Q3	–	Hold	0	–	–	–	2936
2016 Q2	–	Hold	0	–	–	–	2908
2016 Q1	–	Hold	0	–	-$18K	–	3975
2015 Q4	–	Hold	0	–	–	–	2240

Other funds holding NVIV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

IFP Advisors's NVIV Position: Q1 2023 in Review

IFP Advisors sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q1 2023, closing a stake of 1 share — an estimated $1K sold.

IFP Advisors first reported a position in NVIV in Q3 2017 and held it in 4 quarters. The position peaked at $15K in Q3 2017. 20 funds tracked by Wall St. Rank hold NVIV as of Q1 2023.

IFP Advisors reported no remaining InVivo Therapeutics Holdings Corp position as of Q1 2023 after selling out during the quarter.
IFP Advisors sold 1 InVivo Therapeutics Holdings Corp share in Q1 2023, an estimated $1K.
IFP Advisors first reported a position in InVivo Therapeutics Holdings Corp in Q3 2017 and held it in 4 quarters.
IFP Advisors's InVivo Therapeutics Holdings Corp position peaked at $15K in Q3 2017.
20 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q1 2023.

Based on IFP Advisors's 13F filing for Q1 2023, filed 18 Apr 2023.